Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from ImmunityBio ( (IBRX) ).
On February 7, 2025, ImmunityBio’s Compensation Committee approved 2024 executive bonuses for its key officers, reflecting an 80% payout of the target amount, with payments scheduled for March 14, 2025. Additionally, the company announced its 2025 Long-Term Incentive Program, granting stock options and restricted stock units to executives, with awards set to vest over three years, and set new base salary rates effective March 10, 2025.
More about ImmunityBio
ImmunityBio, Inc. is a company involved in biotechnology and pharmaceuticals, focusing on developing innovative immunotherapy solutions.
YTD Price Performance: 26.07%
Average Trading Volume: 5,782,749
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.37B
See more insights into IBRX stock on TipRanks’ Stock Analysis page.
